ADVERTISEMENT
Log in here to read the desired article.
This author has not written his bio yet.
But we are proud to say that Joachim Eeckhout contributed 135 entries already.
Novartis has signed a multi-target oncology discovery deal with Antares Therapeutics, paying $105m upfront for access to the Boston biotech’s small-molecule discovery engine. The agreement could bring Antares up to $1.8bn more in option, development, regulatory and commercial milestones, plus tiered royalties on global net sales that could reach the low double-digit range.
Dutch biotech Leyden Labs has raised €40m from a group of investors to advance its nasal spray approach for protection against influenza and other respiratory viruses.
Merck KGaA has partnered with Versant Ventures to launch Saturnus Bio, a new biotech developing precision medicines for rare genetic cardiomyopathies.
UK-based TRIMTECH Therapeutics has raised an additional $14 million, bringing its total seed financing to $47 million.
Sanofi’s Cenrifki (tolebrutinib) has been approved in the EU as the first disability-targeting medicine for adults with secondary progressive multiple sclerosis (SPMS) without relapses in the previous two years.
The Novo Nordisk Foundation is launching a new European incubator network to turn academic discoveries in cardiometabolic disease into drug development projects, extending the broader European innovation push it set in motion earlier this year through a DKK5.5bn (€736 million) commitment to the BioInnovation Institute (BII).
UK antifungal specialist F2G and Japanese partner Shionogi have announced positive topline results from the global Phase III OASIS trial of olorofim in patients with invasive aspergillosis, a life-threatening fungal infection that mainly affects immunocompromised patients.
After months of regulatory uncertainty, uniQure says the FDA will accept three-year Phase I/II data as the primary basis for an accelerated approval application for AMT-130.
Finnish biotech Aplagon has raised €4.8m to broaden Phase II development of its lead candidate APAC, a first-in-class antiplatelet and anticoagulant therapy for thrombo-inflammatory diseases. The financing will support a new Phase II clinical programme in arteriovenous fistula (AVF) maturation failure in patients with end-stage kidney disease.
Kos Biotechnology Partners has raised US$123m (€106m) for its inaugural global life sciences fund, marking a notable step for Greece’s still young biotechnology financing ecosystem.